Single-cell Omics Market Segmentation:
Application Segment Analysis
By 2035, the oncology sector is estimated to captivate the largest share of 46% in the global single-cell omics market. The growth of the segment can be attributed to the rise in the number of gene therapy trials focusing on genomics in cancer care. According to the American Society of Gene & Cell Therapy, 97.0% of the under-development CAR-T cell therapies belonged to oncology till 2024. Even in the gene therapy pipeline (preclinical to pre-registration), this category captured the highest proportion of 54.0%, accounting for 1123 developments.
End user Segment Analysis
The research organization segment is projected to hold 55% share of the global single-cell omics market over the assessed timeline. Rising investment from both public and private organizations to accelerate the development progress in the research facilities is empowering the segment’s revenue generation. For instance, in March 2023, Schmidt Futures allocated a USD 50.0 million fund to the latest research facility aimed at creating single-cell proteomics technologies for various clinical disciplines, such as Alzheimer’s disease. Such financial support empowers procurement of advanced equipment, such as high-throughput sequencers, single-cell isolation systems, and imaging platforms, ensuring a stable capital influx in this segment.
Our in-depth analysis of the global single-cell omics market includes the following segments:
|
Application |
|
|
Product |
|
|
End user |
|
